BlogThe Market Changes Daily
We help you stay one step ahead.
Founded in 2006, the Institute for Clinical and Economic Review (ICER) is an independent and non-partisan research organization that objectively evaluates the clinical and economic value of prescription drugs, medical tests, and other health care and health care delivery innovations.
What if we told you that formulary and PBM management can help you stop SAVE money and STOP overspending before it hits your bottom line? Now, what if we told you that those savings could dwarf your cherished PBM rebates?
Prozac (fluoxetine) a safe, effective drug that has given millions of patients relief from symptoms of major depression, obsessive-compulsive disorder, panic disorder, and other debilitating conditions. But why are the tablets more expensive than the capsules?
The government issued a confusing new rule designed to curb the use of drug manufacturer coupons, then delayed its implementation until 2021. We feel their pain. Drug coupons are everywhere. You’ll find them in the mail, online, and in most magazines. Many patients,...
You’ve seen the television commercials and glossy magazine ads, recommending a conversation with “your own trusted doctor.” Seems like good advice. But by controlling that conversation – right there in the examining room – Big Pharma is able to sell us drugs we don’t need at prices we can’t afford.
Designed to stifle competition and circumvent rebate deals with Pharmacy Benefit Managers, authorized generics are one of the most profitable market sectors for drug makers, returning $50 for every $1 invested.
The questions of how expensive gene therapies are going to be covered, who will be paying for them, and how our healthcare system can adapt to support getting these cures to those who desperately need them – are not easy questions – but everyone, including the drug companies, are asking them.
Novum Pharmaceuticals was founded in order to take advantage of the way we deliver pharmacy benefits here in America, and their story offers an object lesson in how profiteering by drugmakers drives up health care costs.
The U.S. patent system not only allows but also incentivizes anti-competitive practices, driving up costs for everybody—patients, government payers, and insurers—while at the same time stifling the innovation that high drug prices are supposed to fund.
It was a bad week for transparency. A series of policy defeats means that drug rebates will continue to obstruct pricing transparency and, quite possibly, to drive prescription drug price increases.
A major lawsuit accuses generic drug makers of a price-fixing conspiracy and “billions of dollars of damage” to the US economy… Proof once again that generics now require as much (if not more) vigilance from payers as do brand-name drugs.
High-deductible plans haven’t encouraged employees to shop more effectively for health care because they haven’t been given the tools they need in order to do so.
For years, drug makers, drug wholesalers, pharmacies, and pharmacy benefit managers (also known as PBMs) have thrived thanks to a complex system that conceals profiteering.
The implications of million-dollar drugs are especially worrisome for employers who self-fund health their health plans… and, by extension, for the 60% of covered workers who are in a self-funded plan.
Insulin prices DOUBLED in 5 years, due almost entirely to price increases at the point of sale. Inflation, for the record, is about 2% annually.
Healthcare waste is costing $750 billion per year, and some 60% of employers aren’t doing anything about it. Are you one of them?
Generic drugs are generally much cheaper than brand-name, but that doesn’t mean that generics are inexpensive (or fairly-priced).
Don’t forget that pricing varies from pharmacy to pharmacy—sometimes dramatically. Scripta ensures that patients know where to shop for the best price for a given medication, even if that is at Walmart or other CVS competitors.
A year ago, CVS Health announced a new e-prescription program to help employees pay less for medications—but it is still a case of the fox guarding the hen house.
Scripta partner shares strategies for health care cost containment at the World Health Care Congress in Washington, D.C.